Grant: Innovative Solutions Canada
Galenvs Sciences Inc.
$266,500.00
Magnetic-Based Reagents for Viral RNA Extraction in Clinical and Point-of-Care Applications
FY 2020-21 · 2020-08-24
Summary
COVID-19 Challenge: To develop a proof of concept for The National Research Council Canada (NRC) is seeking a solution for reagents required for nucleic acid sample preparation and rapid and efficient SARS-CoV-2 Ribonucleic Acid (RNA) extraction in order to perform downstream molecular diagnostics of COVID-19 with capability to integrate within existing and/or potential microfluidic platforms for sample-to-answer solutions that can be deployed on the frontline for rapid testing.
Department
Program
Innovative Solutions Canada
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
742964521
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2020-11-23
Agreement Number
955723
Agreement Start Date
2020-08-24
Agreement Title
Magnetic-Based Reagents for Viral RNA Extraction in Clinical and Point-of-Care Applications
Agreement Title (French)
Réactifs à base magnétique pour l'extraction de l'ARN viral dans les applications cliniques et aux points de service
Agreement Type
Grant
Agreement Value
$266,500.00
Amendment Number
0
Coverage
• Support the scale up and growth of Canada's innovators and entrepreneurs by having the federal government act as a first customer. • Stimuler l'expansion et la croissance des innovateurs et entrepreneurs canadiens en faisant du gouvernement fédéral le premier client des innovations canadiennes.
Description
COVID-19 Challenge: To develop a proof of concept for The National Research Council Canada (NRC) is seeking a solution for reagents required for nucleic acid sample preparation and rapid and efficient SARS-CoV-2 Ribonucleic Acid (RNA) extraction in order to perform downstream molecular diagnostics of COVID-19 with capability to integrate within existing and/or potential microfluidic platforms for sample-to-answer solutions that can be deployed on the frontline for rapid testing.
Description (French)
Défi COVID-19 : Développer une preuve de concept pour les réactifs nécessaires à la préparation des échantillons d'acide nucléique et à l'extraction rapide et efficace de l'acide ribonucléique (ARN) SARS-CoV-2 afin d'effectuer des diagnostics moléculaires en aval de COVID-19 avec la possibilité d'intégrer dans des plateformes microfluidiques existantes et/ou potentielles des solutions échantillon-réponse qui peuvent être déployées en première ligne pour des tests rapides.
Expected Results
Grow Canadian companies through direct funding to support early stage, pre-commercial research and development, late stage prototypes, and to accelerate commercialization.
Expected Results (French)
Faire croître les sociétés canadiennes au moyen de financement direct versé pour soutenir la recherche-développement (R-D) précommerciale à un stade précoce et les prototypes à un stade avancé et en accélérer la commercialisation.
Federal Riding
Papineau
Federal Riding (French)
Papineau
Federal Riding Number
24055
NAICS Code
621510
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Innovative Solutions Canada
Program Name (French)
Programme Solutions innovatrices Canada
Program Purpose
Fuel the development and adoption of technological innovation in Canada
Program Purpose (French)
Stimuler le développement et l'adoption de l'innovation technologique au Canada
Recipient Business Number
742964521
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Galenvs Sciences Inc.
Recipient Operating Name
Galenvs Sciences Inc.
Recipient Postal Code
H3N 1Y4
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2020-2021-Q2-955723
Research Organization
National Research Council Canada/Conseil national de recherches Canada
